the “new MOA” where LL primes cold tumors to e

Quote:

---

the “new MOA” where LL primes cold tumors to express PDL one. I think there was a mention there of DNA repair.

---

With the large increase in activated T-cells in the tumor microenvironment the immune system tries to balance things out by increasing Tregs and cell protectants like PD-L1. Completely separate from DNA repair. Chemotherapy and radiation therapy are used to damage tumor cells and kill them but the DNA can repair that damage and help the cell survive. Leronlimab downregulates the PI3K/AKT pathway which disrupts ELF4E which is used for replication and repair of cells. The same process I outlined for a direct effect against the Covid-19 virus.

Quote:

---

I did some research months ago when my uncle had glioblastoma and found a company out of Massachusetts called BPGbio that has a 96 hour infusion for a product yet to be approved that seemed to “prime” cells for DNA repair and I think it’s specific to mitochondrial DNA repair.. my thinking at the time was that LL could have a synergistic effect with this product. Does the DNA repair that CYDY discussed have a similar MOA to this product from BPG? If they are different, how?

---

I took a look at BPG's drug mechanism of action. Cancer preferentially uses mitochondrial glycolysis rather than mitochondrial oxidative phosphorylation to provide the energy required for tumor growth. BPG's drug reverses this potentially slowing tumor growth. CCR5 also promotes glycolysis in cancer cells and blockade switches that.